We are pleased to announce that a research group at our university, in collaboration with Perseus Proteomics Inc., has discovered through animal models that the novel antibody drug candidate “PPMX-T003”—currently under development by the company—has the potential to inhibit the metastasis of colorectal cancer, a condition considered extremely difficult to treat, and effectively suppress tumor growth. This research finding was published in the international academic journal Signal Transduction and Targeted Therapy on August 20, 2026.

For further details, please visit this website.